Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial
IntroductionAcute ischemic stroke (AIS) poses a significant risk to human health. Intravenous thrombolysis and mechanical thrombectomy are essential treatments for AIS, offering substantial benefits for neurological recovery and brain protection. However, their efficacy is often limited by stringent...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1507278/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589849223233536 |
|---|---|
| author | Yunmeng Chen Jingjing Wei Xiao Liang Yue Liu Lina Miao Di Zhao Yunfan Zhang Hongxi Liu Yunling Zhang |
| author_facet | Yunmeng Chen Jingjing Wei Xiao Liang Yue Liu Lina Miao Di Zhao Yunfan Zhang Hongxi Liu Yunling Zhang |
| author_sort | Yunmeng Chen |
| collection | DOAJ |
| description | IntroductionAcute ischemic stroke (AIS) poses a significant risk to human health. Intravenous thrombolysis and mechanical thrombectomy are essential treatments for AIS, offering substantial benefits for neurological recovery and brain protection. However, their efficacy is often limited by stringent time constraints and contraindications, restricting accessibility for certain patient populations. Investigating novel therapeutic strategies is, therefore, crucial. Our team developed Xiongzhitongluo granules specifically for AIS and is conducting a randomized controlled trial (RCT) to validate their effectiveness.Methods and analysisThis multi-center, randomized, double-blind, placebo-controlled clinical trial includes 120 participants randomly allocated to the intervention or placebo group. Participants will receive a 14-day treatment alongside routine medications and will be monitored at multiple time points: days 1, 3, 5, 7, 14, 30, 60, and 90. The primary outcome is the change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 14. Secondary outcomes include the Scandinavian Stroke Scale (SSS), Barthel Index (BI), modified Rankin Scale (mRS), Brief Mini-Mental State Examination (MMSE), and traditional Chinese medicine (TCM) symptom assessment. Safety evaluations will include vital signs and laboratory tests. Data will be recorded using Epidata V3.1 and analyzed with SPSS 26.0.Ethics and disseminationThis study received approval from the Ethics Committee of Xiyuan Hospital, China Academy of Chinese Medical Sciences (2021XLA102-2). Written informed consent was obtained from all participants.Clinical trial registrationhttps://clinicaltrials.gov/, identifier, ChiCTR2200061859. |
| format | Article |
| id | doaj-art-740f46774a574e15aed15911a4dd9e84 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-740f46774a574e15aed15911a4dd9e842025-01-24T07:13:29ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.15072781507278Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trialYunmeng Chen0Jingjing Wei1Xiao Liang2Yue Liu3Lina Miao4Di Zhao5Yunfan Zhang6Hongxi Liu7Yunling Zhang8Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaShenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Afiliated Hospital, Southern University of Science and Technology), Shen Zhen, ChinaXiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaIntroductionAcute ischemic stroke (AIS) poses a significant risk to human health. Intravenous thrombolysis and mechanical thrombectomy are essential treatments for AIS, offering substantial benefits for neurological recovery and brain protection. However, their efficacy is often limited by stringent time constraints and contraindications, restricting accessibility for certain patient populations. Investigating novel therapeutic strategies is, therefore, crucial. Our team developed Xiongzhitongluo granules specifically for AIS and is conducting a randomized controlled trial (RCT) to validate their effectiveness.Methods and analysisThis multi-center, randomized, double-blind, placebo-controlled clinical trial includes 120 participants randomly allocated to the intervention or placebo group. Participants will receive a 14-day treatment alongside routine medications and will be monitored at multiple time points: days 1, 3, 5, 7, 14, 30, 60, and 90. The primary outcome is the change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 14. Secondary outcomes include the Scandinavian Stroke Scale (SSS), Barthel Index (BI), modified Rankin Scale (mRS), Brief Mini-Mental State Examination (MMSE), and traditional Chinese medicine (TCM) symptom assessment. Safety evaluations will include vital signs and laboratory tests. Data will be recorded using Epidata V3.1 and analyzed with SPSS 26.0.Ethics and disseminationThis study received approval from the Ethics Committee of Xiyuan Hospital, China Academy of Chinese Medical Sciences (2021XLA102-2). Written informed consent was obtained from all participants.Clinical trial registrationhttps://clinicaltrials.gov/, identifier, ChiCTR2200061859.https://www.frontiersin.org/articles/10.3389/fmed.2024.1507278/fullacute ischemic strokeXiongzhitongluo granulesrandomized controlled studytraditional Chinese medicinestudy protocolefficacy and safety |
| spellingShingle | Yunmeng Chen Jingjing Wei Xiao Liang Yue Liu Lina Miao Di Zhao Yunfan Zhang Hongxi Liu Yunling Zhang Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial Frontiers in Medicine acute ischemic stroke Xiongzhitongluo granules randomized controlled study traditional Chinese medicine study protocol efficacy and safety |
| title | Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial |
| title_full | Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial |
| title_fullStr | Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial |
| title_full_unstemmed | Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial |
| title_short | Efficacy and safety of Xiongzhitongluo granules in the treatment of acute ischemic stroke: study protocol for a randomized controlled trial |
| title_sort | efficacy and safety of xiongzhitongluo granules in the treatment of acute ischemic stroke study protocol for a randomized controlled trial |
| topic | acute ischemic stroke Xiongzhitongluo granules randomized controlled study traditional Chinese medicine study protocol efficacy and safety |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1507278/full |
| work_keys_str_mv | AT yunmengchen efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT jingjingwei efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT xiaoliang efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT yueliu efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT linamiao efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT dizhao efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT yunfanzhang efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT hongxiliu efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial AT yunlingzhang efficacyandsafetyofxiongzhitongluogranulesinthetreatmentofacuteischemicstrokestudyprotocolforarandomizedcontrolledtrial |